Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) is 20.41% higher on its value in year-to-date trading and has touched a low of $141.98 and a high of $304.39 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The ALNY stock was last observed hovering at around $253.54 in the last trading session, with the day’s gains setting it 29.8%.
Currently trading at $283.34, the stock is 14.81% and 10.40% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 3.14 million and changing 11.75% at the moment leaves the stock 12.24% off its SMA200. ALNY registered 91.23% gain for a year compared to 6-month loss of 3.73%. The firm has a 50-day simple moving average (SMA 50) of $256.6478 and a 200-day simple moving average (SMA200) of $252.4483.
The stock witnessed a 12.88% gain in the last 1 month and extending the period to 3 months gives it a 14.91%, and is 17.20% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.53% over the week and 4.35% over the month.
Alnylam Pharmaceuticals Inc (ALNY) has around 2230 employees, a market worth around $36.86B and $2.25B in sales. Fwd P/E is 189.26. Profit margin for the company is -12.37%. Distance from 52-week low is 99.57% and -6.92% from its 52-week high. The company has generated returns on investments over the last 12 months (-10.47%).
The EPS is expected to grow by 18.93% this year.
Alnylam Pharmaceuticals Inc (ALNY) Top Institutional Holders
894.0 institutions hold shares in Alnylam Pharmaceuticals Inc (ALNY), with institutional investors hold 100.84% of the company’s shares. The shares outstanding are 129.29M, and float is at 124.34M with Short Float at 2.01%. Institutions hold 96.90% of the Float.
The top institutional shareholder in the company is CAPITAL WORLD INVESTORS with over 14.97 million shares valued at $3.64 billion. The investor’s holdings represent 11.8133% of the ALNY Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 12.51 million shares valued at $3.04 billion to account for 9.9159 of the shares outstanding. The other top investors are FMR LLC which holds 12.16 million shares representing 9.5982% and valued at over $2.96 billion, while BLACKROCK INC. holds 7.5692 of the shares totaling 9.55 million with a market value of $2.32 billion.
Alnylam Pharmaceuticals Inc (ALNY) Insider Activity
#####
Alnylam Pharmaceuticals Inc disclosed in a document filed with the SEC on Mar 03 ’25 that Fitzgerald Kevin Joseph (CSO & EVP, Head of Research) sold a total of 1,911 shares of the company’s common stock. The trade occurred on Mar 03 ’25 and was made at $243.73 per share for $0.47 million. Following the transaction, the insider now directly holds 14345.0 shares of the ALNY stock.
Still, SEC filings show that on Mar 04 ’25, Fitzgerald Kevin Joseph (CSO & EVP, Head of Research) disposed off 844 shares at an average price of $241.15 for $0.2 million. The insider now directly holds 13,501 shares of Alnylam Pharmaceuticals Inc (ALNY).
